Gulf War Illness Clinical Trial
— REGIONSOfficial title:
RCT of Duloxetine & Pregabalin for the Treatment of Gulf War Illness in Veterans
Verified date | February 2021 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive. GWI refers to a complex of symptoms that typically include widespread chronic pain, persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep disturbances and unexplained fatigue. These symptoms are similar to that of fibromyalgia syndrome (FMS), another multi-symptom condition. Whereas, effective treatments for GWI have yet to be found, the FDA has approved duloxetine and pregabalin for the treatment of FMS. The lack of progress in finding effective treatments for GWI, and the similarities between GWI and FMS, provides a rationale for determining if these medications can provide relief to Veterans who suffer from GWI. This randomized controlled trial will test the efficacy of Duloxetine and Pregabalin for treating Gulf War Veterans who suffer from GWI.
Status | Terminated |
Enrollment | 112 |
Est. completion date | August 1, 2019 |
Est. primary completion date | August 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 44 Years to 70 Years |
Eligibility | Inclusion Criteria: - Living in Central Texas near Killeen, Austin, Temple or Waco - Served on active military duty and deployed to the Persian Gulf region for some period between August 1990 & July 1991 - English speaking and able to understand the consent form and study questionnaires - Willing to be randomized to treatment and participate in 1-month follow up - men & women between the ages of 43 to 70 - meet Kansas GWI case definition for the diagnosis of GWI - report a baseline score > 4 on a 10-point Pain Visual Analog Scale (VAS) - female participants of childbearing potential must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control (for example, oral contraceptives or Norplant; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam); intrauterine devices; partner with vasectomy; or abstinence) during the study and for 2 months following the last dose of the study drug. [Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause.] Exclusion Criteria: - Unstable or poorly controlled chronic medical illness such as Diabetes type-II, Hypertension (HTN), heart disease, endocrine disorders, narrow angle glaucoma - Significant Central Nervous System disease including transient ischemic attacks (TIAs) or stroke, Dementia, syncopal episodes, severe head trauma, multiple sclerosis - Serious or advanced heart disease or clinically relevant abnormal electrocardiogram (ECG), postural hypotension - Untreated sleep apnea or body mass index placing patients at risk for undiagnosed sleep apnea (BMI> 35 kg/m2) - Diabetes type-I and patients with Diabetes type-II associated with peripheral neuropathy, hepatitis, liver failure/cirrhosis - End stage renal disease - History of hypersensitivity reaction to pregabalin, duloxetine, venlafaxine; active treatment with duloxetine or pregabalin; History of failure of duloxetine or pregabalin at therapeutic doses; history of angioedema reaction to pregabalin - Active systemic infectious disease such as tuberculosis and HIV, shingles - Autoimmune mediated illnesses such as systemic lupus erythematosis, rheumatoid arthritis, scleroderma - History of mental illness requiring hospitalization (depression, bipolar illness, post traumatic stress disorder, history of suicide attempts, psychosis, schizophrenia spectrum); Current major depression of dysthymia; patients lacking capacity to make medical decisions - Use of monoamine oxidase inhibitors (MAOIs) within 2 weeks of evaluation; Active ongoing use of the following agents: desvenlafaxine, fenfluramine, linezolid, milnacipran, phentermine, tryptophan, tramadol, opiates - Current (meets criterion within the last 6 months) for drug or alcohol dependence (except for nicotine and caffeine) - Cancer other than non-melanoma skin cancers - Women who are pregnant or desire to become pregnant, breastfeeding, who use unreliable contraception methods - Those with occupations requiring use and/or operation of hazardous heavy equipment or professional drivers - Patients for whom the potential risk outweighs the potential benefit in the opinion of the treating psychiatrist |
Country | Name | City | State |
---|---|---|---|
United States | Central Texas Veterans Health Care System, Temple, TX | Temple | Texas |
United States | Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX | Waco | Texas |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | Texas A&M University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Multiple and Unreliable | Reliability of measurement is highly suspect and data are not suitable for analysis. | Assessed every 2 weeks up to 34 weeks | |
Primary | Pain by Likert Scale | Likert scale of pain rating | 120 days | |
Secondary | Side Effects | Side effects checklist | Assessed every 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04254627 -
TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset
|
Phase 1 | |
Terminated |
NCT02011542 -
Probiotic (VSL #3) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT03078530 -
Probiotic (Visbiome) for Gulf War Illness
|
Phase 2/Phase 3 | |
Recruiting |
NCT04058275 -
"Immunomodulation in GWI (Phlebotomy)"
|
||
Recruiting |
NCT04255498 -
Understanding GWI: Integrative Modeling
|
Phase 1 | |
Completed |
NCT02782780 -
Cognitive Behavioral Therapy for Insomnia for Gulf War Illness
|
N/A | |
Recruiting |
NCT02983734 -
D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)
|
Phase 2 | |
Recruiting |
NCT05972291 -
Mechanisms of Gulf War Illness
|
N/A | |
Recruiting |
NCT04046536 -
rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)
|
N/A | |
Recruiting |
NCT04182659 -
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|
N/A | |
Recruiting |
NCT05377242 -
Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI
|
N/A | |
Recruiting |
NCT05675878 -
Confirmation of Diet as a Treatment for Gulf War Illness
|
Phase 3 | |
Recruiting |
NCT05736146 -
Validating Gulf War Illness Blood Biomarkers
|
||
Not yet recruiting |
NCT05820893 -
Resistant Potato Starch to Alleviate GWI
|
Phase 2 | |
Active, not recruiting |
NCT05252949 -
OEA for Targeting Lipid Metabolism in GWI
|
N/A | |
Completed |
NCT02378025 -
Treating Chronic Pain in Gulf War Illness
|
N/A | |
Completed |
NCT02865460 -
Coenzyme Q10 Phase III Trial in Gulf War Illness
|
Phase 3 | |
Completed |
NCT02909686 -
Effects of Botanical Microglia Modulators in Gulf War Illness
|
N/A | |
Completed |
NCT01291758 -
Exercise in Gulf War Illness (GWI)
|
||
Completed |
NCT01011348 -
Q10 for Gulf War Veterans
|
N/A |